- lead to
strokes and death. Ryan DH (September 2021). "Next
Generation Antiobesity Medications: Setmelanotide, Semaglutide,
Tirzepatide and Bimagrumab:...
- regenerative, neuroprotective, anti-atherosclerotic, antitumor, antiangiogenic,
antiobesity, and
anxiolytic properties.
Phase I
clinical trials of trodusquemine...
- ATC code A08
Antiobesity preparations,
excluding diet
products is a
therapeutic subgroup of the
Anatomical Therapeutic Chemical classification System...
- (also
known as SR141716;
trade names Acomplia, Zimulti) is an
anorectic antiobesity drug
approved in
Europe in 2006 but was
withdrawn worldwide in 2008 due...
- (November 2016). "Beta3-adrenoreceptor
agonist mirabegron - a
potential antiobesity drug?".
Expert Opinion on Pharmacotherapy. 17 (16): 2125–2127. doi:10...
- PMID 33030356. S2CID 222213936. Ryan DH (September 2021). "Next
Generation Antiobesity Medications: Setmelanotide, Semaglutide,
Tirzepatide and Bimagrumab:...
- It
produces the
pancreatic lipase inhibitor lipstatin, of
which the
antiobesity drug
orlistat is a derivative.
Weibel E,
Hadvary P,
Hochuli E, Kupfer...
- heat. Clapham, J. C.; Arch, J.R.S (2007). "Thermogenic and
metabolic antiobesity drugs:
rationale and opportunities". Diabetes,
Obesity & Metabolism....
- R, et al. (September 2007). "Adipose is a
conserved dosage-sensitive
antiobesity gene". Cell Metabolism. 6 (3): 195–207. doi:10.1016/j.cmet.2007.08.001...
-
appetite suppressants. The
following drugs are
listed as "centrally-acting
antiobesity preparations" in the
Anatomical Therapeutic Chemical classification System:...
